Among children there was an increased risk for acute respiratory illness caused by noninfluenza respiratory pathogens following influenza vaccination compared to unvaccinated children during the same period.
Influenza vaccination in the pediatric emergency department setting appears to be a cost-effective strategy.
Temporary discontinuation of methotrexate after influenza vaccination is associated with improved immunogenicity of vaccination in RA.
Low education and low income are linked to lower uptakes of PCV13 in minorities 65 years and older.
Despite the loss of the live attenuated influenza vaccine, overall immunization rates in children 2-17 remained steady.
The American Academy of Pediatrics recommends against the use of the quadrivalent live attenuated influenza vaccine (LAIV4).
Fewer children were immunized against influenza once the CDC ruled out use of the nasal spray.
Hospitalization risk was increased in infants of vaccinated vs nonvaccinated mothers only during the first 90 days of life.
There is no conclusive evidence to support the use of vaccines for preventing the common cold.
Data from the 2015-2016 season shows that the live attenuated influenza vaccine was ineffective among children ages 2-17.
